COVID-19 in patients with CLL: how can we change the odds?

por Herishanu, Yair, Perry, Chava
Publicado 2021

CLL and COVID-19: light at the end of the tunnel?

por Scarfò, Lydia, Herishanu, Yair
Publicado 2022

Rituximab-Related Pulmonary Toxicity

por Herishanu, Yair, Perry, Chava, Polliack, Aaron
Publicado 2010

The Outcomes of Covid-19 in Patients with CLL during the Omicron Sub-Variants Surge

por Bronstein, Yotam, Levi, Shai, Herishanu, Yair
Publicado 2022

REGEN‐COV antibody combination in patients with lymphoproliferative malignancies and SARS‐CoV‐2 infection

por Bronstein, Yotam, Avivi, Irit, Cohen, Yael C, Feigin, Eugene, Perry, Chava, Herishanu, Yair
Publicado 2022

Correlation between BNT162b2 mRNA Covid-19 vaccine-associated hypermetabolic lymphadenopathy and humoral immunity in patients with hematologic malignancy

por Cohen, Dan, Hazut Krauthammer, Shir, Cohen, Yael C., Perry, Chava, Avivi, Irit, Herishanu, Yair, Even-Sapir, Einat
Publicado 2021

Is There a Role for [(18)F]FDG PET-CT in Staging MALT Lymphoma?

por Cohen, Dan, Perry, Chava, Hazut-Krauthammer, Shir, Kesler, Mikhail, Herishanu, Yair, Luttwak, Efrat, Even-Sapir, Einat, Avivi, Irit
Publicado 2022

Spatial organization and early signaling of the B-cell receptor in CLL

por Shorer Arbel, Yamit, Bronstein, Yotam, Dadosh, Tali, Kamdjou, Talia, Tsuriel, Shlomo, Shapiro, Mika, Katz, Ben-Zion, Herishanu, Yair
Publicado 2022

Lymphocyte activation gene 3: a novel therapeutic target in chronic lymphocytic leukemia

por Shapiro, Mika, Herishanu, Yair, Katz, Ben-Zion, Dezorella, Nili, Sun, Clare, Kay, Sigi, Polliack, Aaron, Avivi, Irit, Wiestner, Adrian, Perry, Chava
Publicado 2017

Lower Patient Anxiety and Unchanged Levels of Adherence to Hemato-Oncologic Treatment in Response to New Measures to Reduce Hospital Exposure Risk to COVID-19

por Sarid, Nadav, Mann, Shir, Herishanu, Yair, Perry, Chava, Cohen, Yael C, Passage, Inna, Neaman, Miriam, Benyamini, Noam, Jean, Maayan, Avivi, Irit
Publicado 2021

Six-month antibody persistence after BNT162b2 mRNA COVID-19 vaccination in patients with chronic lymphocytic leukemia

por Herishanu, Yair, Avivi, Irit, Levi, Shai, Shefer, Gabi, Bronstein, Yotam, Moshiashvili, Miguel Morales, Ziv, Tomer, Scarfò, Lydia, Perry, Chava, Ghia, Paolo
Publicado 2022

The Value of PET/CT in Detecting Bone Marrow Involvement in Patients With Follicular Lymphoma

por Perry, Chava, Lerman, Hedva, Joffe, Erel, Sarid, Nadav, Amit, Odelia, Avivi, Irit, Kesler, Mikhail, Ben-Ezra, Jonathan, Even-Sapir, Einat, Herishanu, Yair
Publicado 2016

COVID-19 Breakthrough Infections in Vaccinated Patients With CLL in Israel

por Yekutiel, Naama, Chodick, Gabriel, Tene, Lilac, Bronstein, Yotam, Grunspan, Moshe, Rivlin, Noa, Ofek, Keren, Cohen, Raanan, Raskin, Leon, Komlosi, Viktor, Herishanu, Yair
Publicado 2023

Proteolysis Targeting Chimeras for BTK Efficiently Inhibit B-Cell Receptor Signaling and Can Overcome Ibrutinib Resistance in CLL Cells

por Shorer Arbel, Yamit, Katz, Ben-Zion, Gabizon, Ronen, Shraga, Amit, Bronstein, Yotam, Kamdjou, Talia, Globerson Levin, Anat, Perry, Chava, Avivi, Irit, London, Nir, Herishanu, Yair
Publicado 2021

Efficacy of a third BNT162b2 mRNA COVID-19 vaccine dose in patients with CLL who failed standard 2-dose vaccination

por Herishanu, Yair, Rahav, Galia, Levi, Shai, Braester, Andrei, Itchaki, Gilad, Bairey, Osnat, Dally, Najib, Shvidel, Lev, Ziv-Baran, Tomer, Polliack, Aaron, Tadmor, Tamar, Benjamini, Ohad
Publicado 2022

Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia

por Herishanu, Yair, Avivi, Irit, Aharon, Anat, Shefer, Gabi, Levi, Shai, Bronstein, Yotam, Morales, Miguel, Ziv, Tomer, Shorer Arbel, Yamit, Scarfò, Lydia, Joffe, Erel, Perry, Chava, Ghia, Paolo
Publicado 2021

Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs

por Gabizon, Ronen, Shraga, Amit, Gehrtz, Paul, Livnah, Ella, Shorer, Yamit, Gurwicz, Neta, Avram, Liat, Unger, Tamar, Aharoni, Hila, Albeck, Shira, Brandis, Alexander, Shulman, Ziv, Katz, Ben-Zion, Herishanu, Yair, London, Nir
Publicado 2020

Correction to Efficient Targeted Degradation via Reversible and Irreversible Covalent PROTACs

por Gabizon, Ronen, Shraga, Amit, Gehrtz, Paul, Livnah, Ella, Shorer, Yamit, Gurwicz, Neta, Avram, Liat, Unger, Tamar, Aharoni, Hila, Albeck, Shira, Brandis, Alexander, Shulman, Ziv, Katz, Ben-Zion, Herishanu, Yair, London, Nir
Publicado 2020

COVID-19 in patients with lymphoproliferative diseases during the Omicron variant surge

por Bronstein, Yotam, Gat, Roi, Levi, Shai, Cohen, Yael C., Luttwak, Efrat, Benyamini, Noam, Shragai, Tamir, Vitkon, Roy, Neaman, Miriam, Eilaty, Nili, Levi, Mor, Trestman, Svetlana, Perry, Chava, Herishanu, Yair, Avivi, Irit
Publicado 2022

Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies

por Shapira, Shiran, Kazanov, Dina, Mdah, Fatin, Yaakobi, Hadas, Herishanu, Yair, Perry, Chava, Avivi, Irit, Itchaki, Gilad, Shacham-Abulafia, Adi, Raanani, Pia, Hay-Levy, Mori, Aiger, Gal, Mashiah, Jacob, Lev-Ari, Shahar, Arber, Nadir
Publicado 2021